NEO Quote, Financials, Valuation and Earnings

Fortrea Holdings, Inc. has a net margin of -14.45% compared to NeoGenomics, Inc.'s net margin of -2.27%. NeoGenomics, Inc.'s return on equity of -12.92% beat Fortrea Holdings, Inc.'s return on equity of -104.76%.

NeoGenomics, Inc. has a consensus price target of $13.94, signalling upside risk potential of 17.72%. On the other hand Fortrea Holdings, Inc. has an analysts' consensus of $13.25 which suggests that it could fall by -25.28%. Given that NeoGenomics, Inc. has higher upside potential than Fortrea Holdings, Inc., analysts believe NeoGenomics, Inc. is more attractive than Fortrea Holdings, Inc..

NeoGenomics, Inc. has a beta of 1.598, which suggesting that the stock is 59.751% more volatile than S&P 500. In comparison Fortrea Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeoGenomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeoGenomics, Inc. pays -- of its earnings as a dividend. Fortrea Holdings, Inc. pays out -- of its earnings as a dividend.

NeoGenomics, Inc. quarterly revenues are $187.8M, which are smaller than Fortrea Holdings, Inc. quarterly revenues of $701.3M. NeoGenomics, Inc.'s net income of -$27.1M is lower than Fortrea Holdings, Inc.'s net income of -$15.9M. Notably, NeoGenomics, Inc.'s price-to-earnings ratio is -- while Fortrea Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeoGenomics, Inc. is 2.13x versus 0.58x for Fortrea Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Incyte Corp. has a net margin of -14.45% compared to NeoGenomics, Inc.'s net margin of 31.05%. NeoGenomics, Inc.'s return on equity of -12.92% beat Incyte Corp.'s return on equity of 31.1%.

NeoGenomics, Inc. has a consensus price target of $13.94, signalling upside risk potential of 17.72%. On the other hand Incyte Corp. has an analysts' consensus of $99.62 which suggests that it could fall by -2.99%. Given that NeoGenomics, Inc. has higher upside potential than Incyte Corp., analysts believe NeoGenomics, Inc. is more attractive than Incyte Corp..

NeoGenomics, Inc. has a beta of 1.598, which suggesting that the stock is 59.751% more volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.810, suggesting its less volatile than the S&P 500 by 18.956%.

NeoGenomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeoGenomics, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.

NeoGenomics, Inc. quarterly revenues are $187.8M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. NeoGenomics, Inc.'s net income of -$27.1M is lower than Incyte Corp.'s net income of $424.2M. Notably, NeoGenomics, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 17.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeoGenomics, Inc. is 2.13x versus 4.24x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings, Inc. has a net margin of -14.45% compared to NeoGenomics, Inc.'s net margin of 8.1%. NeoGenomics, Inc.'s return on equity of -12.92% beat IQVIA Holdings, Inc.'s return on equity of 20.65%.

NeoGenomics, Inc. has a consensus price target of $13.94, signalling upside risk potential of 17.72%. On the other hand IQVIA Holdings, Inc. has an analysts' consensus of $253.95 which suggests that it could grow by 15.07%. Given that NeoGenomics, Inc. has higher upside potential than IQVIA Holdings, Inc., analysts believe NeoGenomics, Inc. is more attractive than IQVIA Holdings, Inc..

NeoGenomics, Inc. has a beta of 1.598, which suggesting that the stock is 59.751% more volatile than S&P 500. In comparison IQVIA Holdings, Inc. has a beta of 1.366, suggesting its more volatile than the S&P 500 by 36.638%.

NeoGenomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeoGenomics, Inc. pays -- of its earnings as a dividend. IQVIA Holdings, Inc. pays out -- of its earnings as a dividend.

NeoGenomics, Inc. quarterly revenues are $187.8M, which are smaller than IQVIA Holdings, Inc. quarterly revenues of $4.1B. NeoGenomics, Inc.'s net income of -$27.1M is lower than IQVIA Holdings, Inc.'s net income of $332M. Notably, NeoGenomics, Inc.'s price-to-earnings ratio is -- while IQVIA Holdings, Inc.'s PE ratio is 30.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeoGenomics, Inc. is 2.13x versus 2.44x for IQVIA Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -14.45% compared to NeoGenomics, Inc.'s net margin of 38.89%. NeoGenomics, Inc.'s return on equity of -12.92% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

NeoGenomics, Inc. has a consensus price target of $13.94, signalling upside risk potential of 17.72%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 2.86%. Given that NeoGenomics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe NeoGenomics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

NeoGenomics, Inc. has a beta of 1.598, which suggesting that the stock is 59.751% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

NeoGenomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. NeoGenomics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

NeoGenomics, Inc. quarterly revenues are $187.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. NeoGenomics, Inc.'s net income of -$27.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, NeoGenomics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeoGenomics, Inc. is 2.13x versus 5.94x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.